MOL4239
M-02
Phase 2 small_molecule completed
Quick answer
MOL4239 for Psoriasis is a Phase 2 program (small_molecule) at Moleculin Biotech with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Moleculin Biotech
- Indication
- Psoriasis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed